Literature DB >> 26621196

Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy.

Yoshihiro Komohara1, Yukio Fujiwara2, Koji Ohnishi2, Motohiro Takeya2.   

Abstract

The macrophage is known to be a multifunctional antigen presenting cells and playing a central role in inflammation. Macrophages infiltrate into malignant tumor tissues in high numbers (the so-called tumor-associated macrophages [TAMs]) and many studies over the past decade have demonstrated that macrophages have protumor functions and are closely related to tumor progression. It has been shown that protumor macrophages that have differentiated through interaction with tumor cells are involved in stem cell niches, immunosuppression, invasion, and metastasis. Consistent with these functions, studies using human tumor samples have demonstrated that a higher density of macrophages, especially macrophages with the M2 phenotype, is closely associated with worse clinical prognosis in many kinds of malignant tumors. Infiltrating TAMs themselves or polarization pathway of TAMs are considered as new therapeutic targets for the therapy of malignant tumors.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Heterogeneity; M2; Polarization; Protumor macrophage

Mesh:

Substances:

Year:  2015        PMID: 26621196     DOI: 10.1016/j.addr.2015.11.009

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  166 in total

1.  Engineering Biomaterials to Direct Innate Immunity.

Authors:  R S Oakes; E Froimchuk; C M Jewell
Journal:  Adv Ther (Weinh)       Date:  2019-02-27

2.  Remodeling of the Extracellular Matrix by Endothelial Cell-Targeting siRNA Improves the EPR-Based Delivery of 100 nm Particles.

Authors:  Yu Sakurai; Tomoya Hada; Shoshiro Yamamoto; Akari Kato; Wataru Mizumura; Hideyoshi Harashima
Journal:  Mol Ther       Date:  2016-09-16       Impact factor: 11.454

3.  M2 macrophages do not fly into a "RAGE".

Authors:  Armando Rojas; Carolina Añazco; Paulina Araya
Journal:  Inflamm Res       Date:  2016-10-03       Impact factor: 4.575

Review 4.  Immunotherapy of Melanoma: Facts and Hopes.

Authors:  Sarah A Weiss; Jedd D Wolchok; Mario Sznol
Journal:  Clin Cancer Res       Date:  2019-03-28       Impact factor: 12.531

5.  CTHRC1 promotes M2-like macrophage recruitment and myometrial invasion in endometrial carcinoma by integrin-Akt signaling pathway.

Authors:  Lu-Ying Li; Ke-Min Yin; Yi-Han Bai; Zhi-Gang Zhang; Wen Di; Shu Zhang
Journal:  Clin Exp Metastasis       Date:  2019-05-22       Impact factor: 5.150

6.  Differential expression of efferocytosis and phagocytosis associated genes in tumor associated macrophages exposed to African American patient derived prostate cancer microenvironment.

Authors:  Hirendra Banerjee; Christopher Krauss; Myla Worthington; Narendra Banerjee; Ray Shawn Walker; Sasha Hodges; Lin Chen; Kuldeep Rawat; Santanu Dasgupta; Somiranjan Ghosh; Santosh Mandal
Journal:  J Solid Tumors       Date:  2019-06-27

Review 7.  Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior.

Authors:  Miles A Miller; Ralph Weissleder
Journal:  Adv Drug Deliv Rev       Date:  2016-06-04       Impact factor: 15.470

Review 8.  Big insights from small volumes: deciphering complex leukocyte behaviors using microfluidics.

Authors:  Daniel Irimia; Felix Ellett
Journal:  J Leukoc Biol       Date:  2016-05-18       Impact factor: 4.962

Review 9.  Advances in engineering local drug delivery systems for cancer immunotherapy.

Authors:  Peter Abdou; Zejun Wang; Qian Chen; Amanda Chan; Daojia R Zhou; Vivienne Gunadhi; Zhen Gu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-07

10.  Phenotypical change of tumor-associated macrophages in metastatic lesions of clear cell renal cell carcinoma.

Authors:  Takanobu Motoshima; Yuji Miura; Nanako Wakigami; Natsuki Kusada; Toshimi Takano; Naoko Inoshita; Toshikazu Okaneya; Yutaka Sugiyama; Tomomi Kamba; Motohiro Takeya; Yoshihiro Komohara
Journal:  Med Mol Morphol       Date:  2017-12-07       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.